• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Dexcom announces availability of G6 for Tricare members as formulary pharmacy benefit

April 13, 2022 By Sean Whooley

G6
G6 from Dexcom

Dexcom (Nasdaq:DXCM) announced that its G6 continuous glucose monitoring (CGM) system will be available through Tricare.

San Diego-based Dexcom’s CGM will be more easily available to military members, their families and retirees with diabetes as a Tricare brand-name formulary pharmacy benefit.

According to a news release, effective mid-April 2022, members with diabetes will be eligible for the Dexcom G6 CGM through the military treatment facility pharmacies at zero copayment, the Tricare retail pharmacy network at a $38 copayment per 30-day supply or through the mail-order/home delivery at a copayment of $34 per 90-day supply.

Dexcom’s G6 was previously available through the Tricare medical benefit by durable medical equipment suppliers, with varying copayment amounts based on the plan. The company said the pharmacy benefit offers a faster process and more consistent copayments for members.

“We are thrilled to make Dexcom G6 more easily accessible to the many military members and their families who rely on Tricare,” Dexcom Chair, President and CEO Kevin Sayer said in the release. “With the pharmacy benefit, Tricare beneficiaries with diabetes can use this game-changing technology to make informed, real-time decisions about their health with little to no out-of-pocket costs.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Dexcom

IN CASE YOU MISSED IT

  • BD’s IV catheters plant in Utah marks 70 years
  • Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
  • Abbott partners with Berry Street to add nutrition coaching to Lingo
  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS